Elicio Therapeutics Inc (ELTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$2.18-7.23%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Elicio aims to extend cash into Q4 2026. It plans a key Phase 2 cancer study readout soon. Positive pancreatic cancer data supports this progress. The stock is very cheap versus peers.
Elicio is losing money and EPS estimates are worsening. The stock dropped 81% from highs. It has no revenue and uncertain cash runway. The Phase 2 results may disappoint or delay.
The market prices in a big decline with implied growth negative over 3-5 years. Our fair value is about $20, reflecting a turnaround chance. We differ by seeing risk in cash and trial outcomes.
Breaks if: Cash runway falls short of Q4 2026
Breaks if: EPS loss worsens beyond -$2.43 in FY27
Breaks if: Phase 2 DFS analysis delayed beyond H1 2026 or negative results
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and has a high risk profile, but it operates in a sector that has favorable momentum.
The market seems to price in a low level of fragility, as there are no significant fragility gates triggered. However, the valuation is considered cheap compared to peers, suggesting that expectations may be low.
Management is focused on advancing clinical trials and extending cash runway, but recent financial performance has been weak. The likelihood of missing expectations is notable, given the high miss probability in this sector.
The long-term thesis hinges on management's ability to execute on trial developments and extend cash runway successfully. Additionally, sector performance from leading companies could influence ELTX's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats impacting the thesis at this time.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
In the next 1 to 3 years, ELTX's performance will depend on clinical trial outcomes and broader sector trends. Not investment advice.